SHATTUCK LABS INC (STTK) — insider trading
Health Care · NASDAQ
SHATTUCK LABS INC (STTK) has 46 reported SEC Form 4 insider transactions in our data, including 5 open-market purchases and 6 open-market sales among the most recent 46 (latest 2026-07-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 12,153 | — | $0 | Form 4 |
| 2026-07-06 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion | 12,153 | $3.57 | $43.4K | Form 4 |
| 2026-07-02 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 410 | — | $0 | Form 4 |
| 2026-07-02 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Open-market sale | 410 | $7.01 | $2.9K | Form 4 |
| 2026-07-02 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion | 410 | $3.57 | $1.5K | Form 4 |
| 2026-07-01 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 100 | — | $0 | Form 4 |
| 2026-07-01 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Open-market sale | 100 | $7.07 | $707 | Form 4 |
| 2026-07-01 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion | 100 | $3.57 | $357 | Form 4 |
| 2026-06-30 | Pandite Arundathy N. | Officer (Chief Medical Officer) | Open-market sale | 30,000 | $7.01 | $210.3K | Form 4 |
| 2026-06-30 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 23,365 | — | $0 | Form 4 |
| 2026-06-30 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Open-market sale | 23,365 | $7.08 | $165.4K | Form 4 |
| 2026-06-30 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion | 23,365 | $3.57 | $83.4K | Form 4 |
| 2026-06-11 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Open-market purchase (derivative) | 208,333 | — | — | Form 4 |
| 2026-06-11 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Open-market purchase (derivative) | 1,041,667 | — | — | Form 4 |
| 2026-06-11 | Ashiya Mona | Director | Open-market purchase (derivative) | 208,333 | — | — | Form 4 |
| 2026-06-11 | Ashiya Mona | Director | Open-market purchase (derivative) | 1,041,667 | — | — | Form 4 |
| 2026-06-09 | SIEGALL CLAY B | Director | Open-market purchase | 62,500 | $4.00 | $250.0K | Form 4 |
| 2026-06-08 | Ashiya Mona | Director | Conversion of derivative (derivative) | 3,073,298 | — | — | Form 4 |
| 2026-06-08 | Ashiya Mona | Director | Conversion of derivative (derivative) | 15,366,490 | — | — | Form 4 |
| 2026-06-08 | Ashiya Mona | Director | Conversion of derivative (derivative) | 3,073,298 | — | — | Form 4 |
| 2026-06-08 | Ashiya Mona | Director | Conversion of derivative (derivative) | 15,366,490 | — | — | Form 4 |
| 2026-06-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Conversion of derivative (derivative) | 3,073,298 | — | — | Form 4 |
| 2026-06-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Conversion of derivative (derivative) | 15,366,490 | — | — | Form 4 |
| 2026-06-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Conversion of derivative (derivative) | 3,073,298 | — | — | Form 4 |
| 2026-06-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC | Director | Conversion of derivative (derivative) | 15,366,490 | — | — | Form 4 |
| 2026-05-29 | Boudreau Helen M | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-29 | SIEGALL CLAY B | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-29 | Ashiya Mona | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-29 | Gibson Neil W | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-29 | Golumbeski George | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-29 | Baker Daniel G. | Director | Grant / award / vesting (derivative) | 81,000 | — | $0 | Form 4 |
| 2026-05-22 | SIEGALL CLAY B | Director | Option exercise / conversion (derivative) | 128,054 | — | — | Form 4 |
| 2026-05-22 | SIEGALL CLAY B | Director | Grant / award / vesting | 128,054 | $1.08 | $138.9K | Form 4 |
| 2026-05-21 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 5,122 | — | — | Form 4 |
| 2026-05-21 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Grant / award / vesting | 5,122 | $1.08 | $5.6K | Form 4 |
| 2026-05-15 | Stout Stephen | Officer (See Remarks) | Option exercise / conversion (derivative) | 12,805 | — | — | Form 4 |
| 2026-05-15 | Stout Stephen | Officer (See Remarks) | Grant / award / vesting | 12,805 | $1.08 | $13.9K | Form 4 |
| 2026-05-12 | Pandite Arundathy N. | Officer (Chief Medical Officer) | Open-market sale | 30,000 | $6.61 | $198.3K | Form 4 |
| 2026-05-12 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 2,032 | — | $0 | Form 4 |
| 2026-05-12 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Open-market sale | 2,032 | $7.01 | $14.2K | Form 4 |
| 2026-05-12 | Shukla Abhinav A. | Officer (Chief Technical Officer) | Option exercise / conversion | 2,032 | $3.57 | $7.3K | Form 4 |
| 2026-05-12 | Neill Andrew R | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 64,027 | — | — | Form 4 |
| 2026-05-12 | Neill Andrew R | Officer (Chief Financial Officer) | Grant / award / vesting | 64,027 | $1.08 | $69.4K | Form 4 |
| 2026-05-12 | Schreiber Taylor | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 25,610 | — | — | Form 4 |
| 2026-05-12 | Schreiber Taylor | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 25,610 | $1.08 | $27.8K | Form 4 |
| 2026-05-10 | Stout Stephen | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 968 | $6.85 | $6.6K | Form 4 |
Ask the chat about STTK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SHATTUCK LABS INC (STTK).
Last updated 2026-07-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.